-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
We Think Zylox-Tonbridge Medical Technology (HKG:2190) Can Afford To Drive Business Growth
We Think Zylox-Tonbridge Medical Technology (HKG:2190) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.
So should Zylox-Tonbridge Medical Technology (HKG:2190) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.
View our latest analysis for Zylox-Tonbridge Medical Technology
How Long Is Zylox-Tonbridge Medical Technology's Cash Runway?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In December 2021, Zylox-Tonbridge Medical Technology had CN¥2.9b in cash, and was debt-free. Looking at the last year, the company burnt through CN¥206m. So it had a very long cash runway of many years from December 2021. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. Depicted below, you can see how its cash holdings have changed over time.
SEHK:2190 Debt to Equity History July 6th 2022How Well Is Zylox-Tonbridge Medical Technology Growing?
Zylox-Tonbridge Medical Technology boosted investment sharply in the last year, with cash burn ramping by 61%. But shareholders are no doubt taking some confidence from the rockstar revenue growth of 544% during that same year. On balance, we'd say the company is improving over time. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How Easily Can Zylox-Tonbridge Medical Technology Raise Cash?
We are certainly impressed with the progress Zylox-Tonbridge Medical Technology has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.
Zylox-Tonbridge Medical Technology's cash burn of CN¥206m is about 5.9% of its CN¥3.5b market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.
So, Should We Worry About Zylox-Tonbridge Medical Technology's Cash Burn?
As you can probably tell by now, we're not too worried about Zylox-Tonbridge Medical Technology's cash burn. For example, we think its revenue growth suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 1 warning sign for Zylox-Tonbridge Medical Technology that potential shareholders should take into account before putting money into a stock.
Of course Zylox-Tonbridge Medical Technology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
仅仅因为一家企业没有赚到钱,并不意味着股票会下跌。例如,虽然亚马逊上市后多年亏损,但如果你从1999年开始买入并持有股票,你就会发大财。但残酷的现实是,许多亏损的公司烧光了所有的现金,破产了。
所以也应该这样Zylox-Tonbridge医疗技术(HKG:2190)股东担心其烧钱?在这份报告中,我们将考虑该公司的年度自由现金流为负,此后将其称为“现金消耗”。第一步是将它的现金消耗与其现金储备进行比较,给我们提供它的“现金跑道”。
查看我们对Zylox-Tonbridge医疗技术的最新分析
Zylox-Tonbridge医疗科技的现金跑道有多长?
一家公司的现金跑道是通过将其现金储备除以现金消耗来计算的。2021年12月,Zylox-Tonbridge医疗科技拥有29亿元人民币现金,并且没有债务。回顾去年,该公司烧掉了2.06亿元人民币。因此,从2021年12月开始,它有一条很长的现金跑道。虽然这只是其烧钱情况的一个衡量标准,但它肯定给我们的印象是,持有者没有什么可担心的。如下所示,你可以看到它的现金持有量是如何随着时间的推移而变化的。
联交所:2190债转股历史2022年7月6日Zylox-Tonbridge医疗技术的发展情况如何?
Zylox-Tonbridge医疗技术公司去年大幅增加了投资,现金消耗增加了61%。但股东们无疑从同年544%的摇滚明星收入增长中获得了一些信心。总的来说,我们会说该公司正在随着时间的推移而不断进步。虽然过去总是值得研究的,但最重要的是未来。因此,看看我们的分析师对该公司的预测是很有意义的。
Zylox-Tonbridge医疗技术公司筹集现金有多容易?
Zylox-Tonbridge医疗技术在过去一年中取得的进步给我们留下了深刻的印象,但也值得考虑的是,如果它想要筹集更多现金来支持更快的增长,成本会有多高。发行新股或承担债务是上市公司为其业务筹集更多资金的最常见方式。许多公司最终发行新股,为未来的增长提供资金。我们可以将一家公司的现金消耗与其市值进行比较,以了解一家公司需要发行多少新股才能为一年的运营提供资金。
Zylox-Tonbridge医疗技术公司2.06亿元的现金消耗约占其35亿元人民币市值的5.9%。鉴于这只是一个相当小的比例,该公司很可能很容易通过向投资者发行一些新股,甚至通过贷款来为下一年的增长提供资金。
那么,我们应该担心Zylox-Tonbridge医疗技术公司的烧钱吗?
正如你现在可能已经知道的那样,我们并不太担心Zylox-Tonbridge医疗技术公司的烧钱。例如,我们认为它的收入增长表明该公司正走在一条良好的道路上。虽然它不断增加的现金消耗并不是很好,但本文提到的其他因素足以弥补这一指标的疲软。在考虑了这份报告中提到的各种指标后,我们对该公司如何使用现金相当满意,因为它似乎有望在中期内满足其需求。读者在投资股票之前需要对商业风险有一个良好的了解,我们已经发现Zylox-Tonbridge医疗技术公司的1个警告标志潜在股东在将资金投入股票之前应该考虑到这一点。
当然了Zylox-Tonbridge医疗技术公司可能不是最值得购买的股票。所以你可能想看看这个免费拥有高股本回报率的公司的集合,或内部人士正在购买的这份股票清单。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧